This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Adams, R. A. Articles by Hellerstein, E. E. Search for Related Content PubMed PubMed Citation Articles by Adams, R. A. Articles by Hellerstein, E. E.

Serial Transplantation of Burkitt's Tumor (EB3) Cells in Newborn Syrian Hamsters and Its Facilitation by Antilymphocyte Serum¹

The Children's Cancer Research Foundation and the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115

The intraperitoneal or subcutaneous injection of cultured Burkitt's tumor cells into newborn Syrian hamsters treated with antilymphocyte serum has resulted in the development of serially transplantable tumors. Tumor sublines maintained by serial subcutaneous and intraperitoneal transplantation are currently in their 45th and 49th passages, respectively. The administration of antilymphocyte serum in each passage has been required for progressive tumor growth. Immunofluorescence evidence indicates that the tumor cells have retained their human species-specific antigenicity throughout serial passage. Histologically, the tumors are invasive, metastatic, lack the "starry sky" appearance considered typical of Burkitt's tumor, and have not progressed to frank leukemia despite some evidence of involvement of the marrow by tumor cells. Cultured Burkitt's tumor cells were also serially transplantable in untreated newborn hamsters but only by the intracranial route. However, such serial intracranial transplantation was considered unsatisfactory because it could not be sustained beyond 14 passages. These experiments suggest that antilymphocyte serum may potentiate transplantation approaches to the experimental study of human neoplasia.

¹ Supported in part by research Grants C-6516 from the National Cancer Institute and Fr-05526 from the Division of Research Facilities and Resources, NIH; the legacy of Loula D. Lasker; the Albert and Mary Lasker Foundation, New York; and the Alvan T. and Viola D. Fuller Cancer Research Unit Grant, American Cancer Society (Massachusetts Division), Inc.

Received 3/21/69. Accepted 6/24/69.